Immuron partnering with Walter Reid Army Institute of Research to test Travelan against Shigella, ETEC, Vibrio cholerae and Campylobacter jejuni isolates (2020, WRAIR's Investigator's Dispatch)
The WRAIR provides unique research capabilities and innovative medical solutions to a range of Force Health Protection and Readiness challenges currently facing U.S. Service Members, along with threats anticipated during future operations.
https://www.immuron.com.au/assets/files/Diarrheal_Diseases.pdf
Filter by Year:
- Immuron partnering with Walter Reid Army Institute of Research to test Travelan against Shigella, ETEC, Vibrio cholerae and Campylobacter jejuni isolates (2020, WRAIR's Investigator's Dispatch)
- Immuron (ASX:IMC) enters research agreement with Monash University
- Walter Reid Army Institute of Research 2019 Year in Review
- Immuron reveals anti-COVID potential, raises $28 million
- Diarrhea: A major health issue for Americans travelling abroad
- Could Immuron’s (ASX:IMC) traveller’s diarrhoea treatment be used to fight COVID-19?
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
